Navigation Links
TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products
Date:11/18/2009

EAST GRINSTEAD, West Sussex, U.K. and CLEVELAND, Nov. 18 /PRNewswire/ -- TREK Diagnostic Systems, a Magellan Biosciences business and premier provider of diagnostic systems and susceptibility products for microbiology labs, has expanded its East Grinstead, U.K., manufacturing and research and development facility to meet increasing global demand for its Sensititre® product line for susceptibility and identification testing. The expanded facility has been fully validated, and will continue to deliver the same high-quality Sensititre products, including the popular Sensititre microbroth dilution plates used in clinical and veterinary microbiology laboratories worldwide.

Just a short distance from TREK's original U.K. location, the new facility at Units 17 - 19 Birches Industrial Estate, East Grinstead, manufactures standard and custom susceptibility plates. Customers use these plates to determine what drugs and dosage levels are required to treat bacterial and yeast infections. Since the tests match the treatment course with the appropriate drugs, this helps address the growing problem of drug resistance.

More than 100 people, including East Grinstead Town Councillor Bob Mainstone, representatives from U.K. Trade and Investment and the town government, TREK employees and their families, attended a grand-opening celebration on Monday, hosted by President of Magellan Clinical Diagnostics, James Whelan. The event included a ribbon-cutting ceremony, site tour, and fun, learn-about-microbiology activities for children.

"We outgrew our previous facility thanks to increasing demand for our expanding line of susceptibility products, which provide our customers with the cost-effective, and reliable microbiology results they need to make more-informed treatment decisions," said James Whelan. "The proliferation of drug-resistant infections means that clinicians and infection-control experts are looking to us to increase reportable and non-reportable compounds and treatment options that they can evaluate. We have a number of new IVD and RUO plates in development that we hope to launch in 2010, including a Mycobacterium tuberculosis susceptibility plate for first- and second-line drugs."

During his remarks, Mr. Whelan spoke of TREK's decision to build the new facility in East Grinstead, "We have been a part of the community here for more than 30 years, and we're proud of our seasoned, experienced workforce. So when it came time to choose a location where we could expand, East Grinstead was the natural choice. Our new facility gives us the capacity to meet customer needs and allows for future expansion." Currently, 69 of TREK's 180 employees work at the East Grinstead location.

Commenting on the expansion, U.K. Minister for Trade, Investment and Small Business Lord Davies of Abersoch said in a statement, "The U.K. not only has the largest pharmaceuticals industry in Europe, it is also the number one location in Europe for R&D. Globally, one in five of the world's medicines were developed in the U.K. Although the U.K. accounts for just three percent of the global pharmaceutical market, we attract 10 percent of its R&D. I warmly welcome Magellan Bioscience's decision to expand its operations in the U.K. and look forward to hearing more about its successes."

Over the past 18 months, TREK has introduced a number of new in vitro diagnostics (IVD) plates, including a GRAM positive plate used in MRSA detection, which is FDA-cleared for D-Test and Cefoxitin screening; YeastOne plates available with five IVD-cleared antifungal compounds: itraconazole, fluconazole, 5-flucytosine, voriconazole and caspofungin; as well as new plates for research use only (RUO).

About the Sensititre Product Line

TREK's signature Sensititre product line for susceptibility and identification testing enables labs to test -- on a single cost-effective, LIS-compatible system -- more FDA-cleared antimicrobial drugs than on any other automated platform against the widest range of non-fastidious and fastidious bacteria and yeasts. This saves microbiology labs from having to use multiple off-line test procedures to obtain accurate susceptibility data. In order to increase reportable compounds and treatment options for clinicians, TREK obtains FDA clearance where feasible and appropriate. TREK often gets early access to the latest therapeutics because pharmaceutical companies use the Sensititre system during drug development. TREK's platform is also the system-of-choice for global surveillance initiatives, including NARMS (National Antimicrobial Resistance Monitoring System). TREK offers a full range of standard and custom Sensititre plates featuring 18- to 24-hour incubation, true MIC endpoints, and on-scale QC ranges, making susceptibility testing a viable procedure for virtually any size laboratory. The Vizion® system adds easy-to-read digital imaging capability to take the guesswork out of reading susceptibility results. Small minimum order quantities allow for better cost and inventory control. To learn more about custom plates, call customer service toll-free at 800 871-8909. Outside the US and Canada, dial +44 (0) 1342-318777 or e-mail: mmansfield@trekds.co.uk

<p>About TREK Diagnostic Systems (www.trekds.com)

A Magellan Biosciences clinical-diagnostics business dedicated to serving the unique needs of microbiology customers, TREK Diagnostic Systems is a premier provider of advanced systems and consumables for blood culture and antimicrobic-susceptibility testing. Hospital-based, reference, and other microbiology labs trust our products to identify pathogens in patients' blood, and to determine what antimicrobial therapies are effective against them. Clinical, research, pharmaceutical, and veterinary customers count on our staff's microbiology expertise, lab-process savvy, and reliable support to help them address the serious and growing problem of drug-resistant infections. We deliver our advanced technology worldwide as flexible solutions that provide fast, consistent results, while reducing lab and pharmacy costs and improving patient care. Headquartered in Cleveland, Ohio, TREK has additional facilities in Sun Prairie, Wisconsin, and East Grinstead, U.K.

SOURCE TREK Diagnostic Systems


'/>"/>
SOURCE TREK Diagnostic Systems
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
2. Strategic Diagnostics Updates Roth Conference Presentation Time
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
5. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
8. Imaging Diagnostic Systems Generates Cash From Building Sale
9. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
10. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
11. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 NxGen MDx announced today that it brought its ... house, we,ve been able to improve customer service through shortened turnaround times ... Alan Mack , CEO of NxGen MDx. ... , A decrease in turnaround ... to more job opportunities at the Grand Rapid headquarters. The ...
(Date:12/5/2016)... -- Research and Markets has announced the addition ... Markets and Companies" to their offering. ... , , ... genome variations, development of sequencing technologies, and their applications. Current ... developing them. Various applications of sequencing are described including those ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension for ... funded research and development is welcome news for the photonics community, say leaders ... As part of the National Defense Authorization Act (NDAA) compromise agreement finalized today ...
(Date:12/4/2016)... 2016  In five studies being presented today during ... and Exposition in San Diego , ... the delivery of life-saving treatments to patients with a ... to carry therapies directly to the sites in the ... a substantial advantage over traditional, systemic methods. The studies ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/22/2016)... -- According to the new market research report "Biometric System ... Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and ... expected to grow from USD 10.74 Billion in 2015 to reach USD ... 2022. Continue Reading ... ...
(Date:11/17/2016)...  AIC announces that it has just released a new white paper authored by ... plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can ...
Breaking Biology News(10 mins):